InvestorsHub Logo
Followers 657
Posts 83653
Boards Moderated 0
Alias Born 05/25/2008

Re: sal32647 post# 123

Thursday, 06/15/2023 11:21:55 PM

Thursday, June 15, 2023 11:21:55 PM

Post# of 230
We look forward to receiving feedback from FDA on our End of Phase 2 meeting package by the end of June 2023. Assuming positive feedback, we plan to quickly initiate our DMT310 Phase 3 program in moderate-to-severe acne."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DRMA News